JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

JNJ

225.91

+0.55%↑

UNH

362.52

-1.67%↓

TMO

465.38

+0.08%↑

ISRG

450.47

+0.05%↑

ABT

87.21

-0.76%↓

Home・Akcijų sąrašas・Erasca Inc

Search

Erasca Inc

Atidarymo kaina

10 -6.37

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.93

Max

10.37

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.5M -29M
Darbuotojai	103
EBITDA	-2M -32M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+101.4% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.1B 6B
Ankstesnė atidarymo kaina	16.37
Ankstesnė uždarymo kaina	10

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.39 / 1.44 Palaikymas ir pasipriešinimas

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-04 22:17; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

2026-05-04 23:47; UTC

Uždarbis

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

2026-05-04 23:40; UTC

Rinkos pokalbiai

Gold Steady Amid Likely Technical Recovery -- Market Talk

2026-05-04 22:44; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Jim Beyer To Be Chief Executive of Combined Company

2026-05-04 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Pro Forma Market Capitalization About A$10.7 Billion

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Shareholders to Own About 51% of Combined Company

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Board Unanimously Endorsed, Supported Deal

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Deal Unanimously Recommended by Vault Board

2026-05-04 22:39; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources to Acquire All Ordinary Shares in Vault

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources, Vault Minerals Agree to Merger of Equals

2026-05-04 22:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

2026-05-04 22:26; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

2026-05-04 22:02; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

2026-05-04 22:00; UTC

Rinkos pokalbiai

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

2026-05-04 21:52; UTC

Uždarbis

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Some Sectors More Affected Than Others>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

2026-05-04 21:49; UTC

Uždarbis

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

2026-05-04 21:43; UTC

Uždarbis

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

2026-05-04 21:41; UTC

Uždarbis

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

2026-05-04 21:40; UTC

Uždarbis

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

101.4% į viršų

12 mėnesių prognozė

Vidutinis 20.2 USD 101.4%

Aukščiausias 30 USD

Žemiausias 9 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

9

Pirkti

1

Laikyti

1

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Kitos sektoriaus akcijos

JNJ

Johnson and Johnson

225.91

UNH

UnitedHealth Group Inc

362.52

TMO

Thermo Fisher Scientific Inc

465.38

ISRG

Intuitive Surgical Inc

450.47

ABT

Abbott Laboratories

87.21

Live chat